Review
Repaglinide: a short acting insulin secretagogue for postprandial hyperglycaemia
Affiliations
- PMID: 12432213
Item in Clipboard
Review
Repaglinide: a short acting insulin secretagogue for postprandial hyperglycaemia
J Postgrad Med.
2002 Jul-Sep.
Free article
No abstract available
Similar articles
-
[Antidiabetic drug at every meal. Repaglinide is especially recommended for slender type 2 diabetic patients].MMW Fortschr Med. 2000 Jul 20;142(28-29):29-30. MMW Fortschr Med. 2000. PMID: 10959157 German.
-
Modification of beta-cell response to different postprandial blood glucose concentrations by prandial repaglinide and combined acarbose/repaglinide application.Diabetes Nutr Metab. 2004 Jun;17(3):137-42. Diabetes Nutr Metab. 2004. PMID: 15334790 Clinical Trial.
-
Repaglinide for type 2 diabetes mellitus.Med Lett Drugs Ther. 1998 May 22;40(1027):55-6. Med Lett Drugs Ther. 1998. PMID: 9618664 No abstract available.
-
The role of prandial glucose regulation with repaglinide in addressing the problem of hypoglycemia in the treatment of type 2 diabetes.J Assoc Physicians India. 2001 Jan 25;49 Spec No:54-61. J Assoc Physicians India. 2001. PMID: 11235607 Review. No abstract available.
-
Current understanding regarding the role of repaglinide in post-prandial hyperglycemia.J Assoc Physicians India. 2001 Jan 25;49 Spec No:50-3. J Assoc Physicians India. 2001. PMID: 11235606 Review. No abstract available.
Cited by
-
Kir6.2-dependent high-affinity repaglinide binding to beta-cell K(ATP) channels.Br J Pharmacol. 2005 Feb;144(4):551-7. doi: 10.1038/sj.bjp.0706082. Br J Pharmacol. 2005. PMID: 15678092 Free PMC article.
-
The pregnane X receptor agonist St John's Wort has no effects on the pharmacokinetics and pharmacodynamics of repaglinide.Clin Pharmacokinet. 2011 Sep;50(9):605-11. doi: 10.2165/11587310-000000000-00000. Clin Pharmacokinet. 2011. PMID: 21827215 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
